Watch | COVID-19 Bulletin: Another Indian Firm Gets Approval for Trials of Potential COVID Drug
Pawanjot Kaur
Real journalism holds power accountable
Since 2015, The Wire has done just that.
But we can continue only with your support.
Indian pharmaceutical Strides Pharma Science has received regulatory approval to start clinical trials of antiviral drug Favipiravir, which has been touted as a potential treatment for COVID-19. The company has received approval from the Drug Controller General of India to conduct human studies of favipiravir in the country.
Favipiravir is manufactured under the brand name Avigan by a unit of Japan’s Fujifilm Holdings. Earlier this month, Glenmark Pharmaceuticals became the first pharma company in India to get the nod to conduct trials on the drug. The results of this study are expected by July or August.
The Wire is now on WhatsApp. Follow our channel for sharp analysis and opinions on the latest developments.